Duchenne Muscular Dystrophy: Diagnosis, Treatment, and Emerging Therapies

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Form ImageneBio

Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

Home
/
update
/
details

Thermo Fisher Scientific Unveils CTS™ Detachable Dynabeads™ CD4 and CD8 for Advanced Cell Therapy

NextEdge Admin

05 Dec 2024

2 min 27 sec

Dynabeads™,cell therapy,CAR-T cell solutions

Thermo Fisher Scientific has launched the Gibco™ CTS™ Detachable Dynabeads™ CD4 and CTS Detachable Dynabeads CD8, enhancing its CTS Detachable Dynabeads platform. These cutting-edge products prioritize cell quality and workflow flexibility, enabling developers to optimize therapies and accelerate their path to patients in need.

The new CTS Detachable Dynabeads CD4 and CD8 are designed to isolate CD4+ and CD8+ T cells efficiently, ensuring high purity and yield while minimizing cell stress. These cells play a critical role in CAR-T therapies, with research showing that a balanced CD4+/CD8+ ratio enhances therapeutic efficacy. When paired with the CTS Detachable Dynabeads Release Buffer, this system offers a cGMP-compliant, first-of-its-kind active release mechanism suitable for process development, clinical trials, and commercial production.

By integrating into Thermo Fisher’s modular and automated cell therapy workflows, including the Gibco CTS DynaCellect™ Magnetic Separation System, the platform streamlines manufacturing, reducing time for downstream steps. These innovations give developers greater control over cell purity, yield, and phenotype, critical for creating life-changing treatments for complex diseases like blood cancers.

Sara Henneman, general manager of Thermo Fisher’s cell culture and therapy business, noted the growing demand for CAR-T cell solutions, with a 125% increase in clinical trials from 2016 to 2022. Dynabeads technology is already used in over 200 clinical trials and multiple approved cell therapies, positioning this platform as a leader in advancing cell therapy innovation.

Thermo Fisher’s CTS products meet cGMP standards, ensuring regulatory compliance, traceability, and a seamless transition from research to commercialization.